Internal auditory canal meningioma

Summary

Internal auditory canal meningioma (MONDO:0003722) is a disease. A subtype of middle cranial fossa meningioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	internal auditory canal meningioma
Mondo ID	MONDO:0003722
DOID	DOID:5990
NCIT	C5307
UMLS	C1334227
MedGen	235221
GARD	0023633
Anatomy (UBERON)	UBERON:0011859
Is cancer (heuristic)	no

Also known as: internal acoustic meatus meningioma (disease) · meningioma (disease) of internal acoustic meatus · meningioma of internal auditory canal · meningioma of the internal auditory canal

Disease family

This is a subtype of middle cranial fossa meningioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › skeletal system disorder › middle cranial fossa meningioma › internal auditory canal meningioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.